Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance

Key Points

• FY2026 guidance: Bioventus raised its EPS outlook to $0.73–$0.77 (above the $0.72 consensus) and guided revenue of $600–$610 million, roughly in line with the $600.7M consensus.
• Analyst sentiment: Barrington Research initiated coverage with an "outperform" rating and $13 target, and the stock carries an average "Buy" consensus from four analysts with a $13.75 target.
• Stock and ownership: Shares opened at $8.47 (market cap ~$701M) and carry a negative trailing P/E, while institutional investors own about 62.9% of the stock with recent large stake increases (e.g., Nantahala raised its holdings to ~5.28M shares, ~$35M).

Bioventus (NYSE:BVS - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.730-0.770 for the period, compared to the consensus EPS estimate of 0.720. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $600.7 million.

Analyst Upgrades and Downgrades

Separately, Barrington Research assumed coverage on Bioventus in a research report on Monday, February 9th. They set an "outperform" rating and a $13.00 target price for the company. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $13.75.

Bioventus Price Performance

Shares of Bioventus stock opened at $8.47 on Thursday. The stock has a market capitalization of $701.00 million, a price-to-earnings ratio of -13.89 and a beta of 0.80. The firm's 50-day moving average price is $8.07 and its two-hundred day moving average price is $7.47. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus has a 1-year low of $5.81 and a 1-year high of $11.25.

Institutional Trading of Bioventus

Large investors have recently made changes to their positions in the business. Nantahala Capital Management LLC raised its holdings in shares of Bioventus by 28.0% in the second quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company's stock valued at $34,959,000 after buying an additional 1,155,192 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Bioventus in the 4th quarter valued at about $2,886,000. Kent Lake PR LLC acquired a new stake in Bioventus in the 2nd quarter valued at about $2,317,000. Kennedy Capital Management LLC raised its stake in shares of Bioventus by 219.6% in the third quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company's stock worth $3,088,000 after acquiring an additional 317,157 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Bioventus during the third quarter worth approximately $1,372,000. Institutional investors own 62.94% of the company's stock.

Bioventus Company Profile

Bioventus, Inc NYSE: BVS is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus's product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.